Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives

Manojkumar Bupathi
Daniel H Ahn
Tanios Bekaii-Saab

Department of Medical Oncology, Richard Solove Research Institute and James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Abstract: Metastatic colorectal cancer (mCRC) is a prevalent disease for which combination cytotoxic chemotherapy is the mainstay of treatment. With the use of targeted therapy, including anti-angiogenic agents, there have been significant improvements in overall outcome of patients with mCRC. Bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor ligand A, is approved for use in mCRC patients in both the first and second lines of therapy. With a better understanding of the disease through molecular profiling, identification of prognostic biomarkers may lead to better patient selection with improved outcomes for those affected by this disease.

Keywords: VEGF, colon, rectum, cancer

Introduction

Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer-related deaths in the US. In 2014, there were 136,830 new cases of CRC and 50,310 CRC-related deaths in the US. While patients diagnosed with early-stage CRC (stage I–III) have good long-term outcomes with 5-year survival exceeding 50%, those diagnosed with metastatic disease have poor outcomes with a 5-year survival rate that remains under 12%. However, over the past several years, advancements in therapeutic approaches have led to an improvement in patient outcomes with a median overall survival (OS) approaching 3 years. This is largely due to the increase in availability of active regimens with the incorporation of targeted therapy, including anti-angiogenic agents.

Background on VEGF inhibition

Angiogenesis is a mechanism by which tumor cells can proliferate and is controlled by vascular endothelial growth factor (VEGF), primarily VEGF-A (Figure 1). Elevated levels of VEGF-A are associated with metastatic disease of the liver and lymph nodes. Furthermore, in addition to its association with an overall poor prognosis, findings suggest that expression levels may be predictive of more aggressive distant metastatic disease. Takahashi et al showed that the expression of VEGF and its receptor was higher in metastatic disease, correlated with time to progression. VEGF targeting agents have been combined with other chemotherapy agents, leading to improved outcomes in several solid tumor malignancies, including gastric, lung, colon, rectum, and ovary. Based on multiple large, randomized Phase III studies, there are three
approved anti-VEGF therapies in metastatic colorectal cancer (mCRC): bevacizumab, ziv-aflibercept, and ramucirumab.10–12

**Role of RAS in choice of therapy**

Epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase, which binds to different ligands (Figure 1).13 Upon binding to its receptor, the structure is changed leading to downstream autophosphorylation and activation of intracellular signaling cascade, specifically the mitogen-activated protein kinase and phosphoinositide 3-kinase pathways. Activation and downstream phosphorylation of the mitogen-activated protein kinase and phosphoinositide 3-kinase pathways lead to tumor cell proliferation, anti-apoptosis, activation of invasion and metastasis, and tumor-induced neoangiogenesis.14

EGFR is an important therapeutic target in patients with mCRC but is only active in a specified subset of patients. KRAS, a proto-oncogene, is a downstream signaling component of EGFR that is involved in cell proliferation, apoptosis, and tumor-induced neoangiogenesis (Figure 1). One-third of patients with CRC have a mutation in exon 2 of KRAS, and 15% were found to have an additional mutation at exons 3 and 4 of KRAS and exons 2, 3, and 4 of NRAS.15–17 Given these findings, it is now recommended that extended RAS testing be done for all patients prior to initiation of first-line therapy or at least prior to initiation of anti-EGFR therapy. Further, KRAS and NRAS mutational status has been shown to predict the outcome of patients treated with anti-EGFR agents.18 mCRC patients who are wild-type (WT) for RAS have had improvement in OS, progression-free survival (PFS), and response rate (RR) when treated with cetuximab or panitumumab as single agent or in combination with chemotherapy.19,20 By contrast, patients who have RAS mutations and were treated with anti-EGFR therapy tend to have worse outcomes. WT RAS is predictive of response to anti-EGFR therapy compared with RAS-mutated patients who do not respond. Furthermore, it is clear that patients with a BRAF V600E mutation (~5% of all patients) have a poor prognosis regardless of the type of treatment they receive, except for those who have microsatellite-high tumors. The predictive value of BRAF mutations and response to anti-EGFR therapy have been controversial.21,22 Neither RAS nor BRAF mutations have any predictive role for bevacizumab or other VEGF inhibitors.

**Treatment options of metastatic disease**

**The role of chemotherapy**

The OS for patients with untreated mCRC is ~6 months; however, with the use of combinations of cytotoxic chemotherapy and targeted agents, this has been improved to close to 3 years from a historical 12-month period with 5-fluorouracil (5-FU) alone.23 The primary backbone of therapy for mCRC patients is 5-FU, which is a pyrimidine analog that interrupts DNA and RNA synthesis. 5-FU is normally administered as a bolus with leucovorin (LV), which is a folate analog that stabilizes thymidylate synthase and enhances the activity of 5-FU. 5-FU/LV has efficacy for patients with mCRC; however, in the metastatic setting when it is combined with a platinum derivative, oxaliplatin, or a topoisomerase inhibitor, irinotecan (IFL), there are improvements in patients’ PFS and OS. One of the first studies to demonstrate an advantage for combination chemotherapy is that of bolus 5-FU and IFL that was associated with an improved RR and OS compared to bolus 5-FU alone (49% vs 31% [P<0.001] and 17.4 vs 14.1 months [P=0.031], respectively).24 Another study demonstrated that the combination of infusional 5-FU with oxaliplatin (FOLFOX) led to an improvement in median PFS and RR when compared to 5-FU (9.0 vs 6.2 months [P=0.0003] and 50.7% vs 22.3% [P=0.0001], respectively).25 Unfortunately, this study did not demonstrate a clear survival advantage. The combination of all the three agents was explored with 5-FU, oxaliplatin, and IFL (FOLFOXIRI) demonstrated an improvement in RR, OS, and PFS when compared to infusional 5-FU and IFL (60% vs 34%, P<0.0001; median OS 22.6 vs 16.7 months,
hazard ratio [HR] 0.70, \( P=0.032 \); median PFS 9.8 vs 6.9 months, HR 0.63, \( P=0.0006 \). Wider utilization of this regimen has been limited by its potential for significant toxicities.

The role of bevacizumab in the first-line treatment of mCRC

Bevacizumab is a humanized monoclonal antibody that binds to and neutralizes all human VEGF-A. This agent was first introduced in clinical trials in 1997. The first Phase I study suggested that bevacizumab as a single agent was relatively non-toxic and combining it with standard chemotherapy did not seem to exacerbate chemotherapy-related toxicities.\(^{27,28}\) Bevacizumab was investigated at different schedules and in combinations with a variety of chemotherapeutic regimens (5-FU, FOLFIRI, FOLFOX, or FOLFOXIRI). Bevacizumab combined with chemotherapy in the first-line setting demonstrated an improvement in the outcome of patients with mCRC.\(^{29}\) First, Kabbinavar et al conducted a randomized Phase II study to evaluate the efficacy and safety of bevacizumab with 5-FU/L V.\(^{29}\) In this three-arm study, a total of 104 enrolled patients were randomized to receive the following: 1) 5-FU/L V (control arm), 2) 5-FU/L V + bevacizumab at 5 mg/kg, or 3) 5-FU/L V + bevacizumab at 10 mg/kg. Compared to the control arm, patients who received bevacizumab, regardless of the dose, experienced higher RRs and longer median time to disease progression and OS (low-dose arm: 40%, PFS 9 months, OS 21.5 months; high-dose arm: 24%, PFS 7.2 months, OS 16.1 months).\(^{29}\)

Bevacizumab in combination with doublet chemotherapy

Based on prior results, the combination of bevacizumab with 5-FU/L V is active in patients with mCRC. It was also known that IFL with 5-FU/L V improves outcomes in mCRC patients.\(^{30}\) From this, Hurwitz et al conducted a Phase III randomized trial.\(^{31}\) In the study, IFL + bevacizumab (bev) was investigated in 813 patients with advanced CRC. Patients were randomized and received IFL + placebo or IFL + bev. Findings demonstrated significant improvements in OS, PFS, and RR in patients who received bev (20.3 vs 15.6 months, HR 0.66, \( P<0.001 \); 10.6 vs 6.2 months, HR 0.54, \( P<0.001 \); 44.8% vs 34.8%, \( P=0.004 \), respectively).\(^{31}\) Another key trial that evaluated bevacizumab with doublet chemotherapy was Eastern Cooperative Oncology Group 3200 study.\(^{32}\) This study enrolled patients who were previously treated with IFL and found that OS (12.9 vs 10.8 months; \( P=0.0011 \)), PFS (7.3 vs 4.7 months; \( P=0.0001 \)), and RR (22.7% vs 8.6%; \( P<0.0001 \)) were significantly better with FOLFOX/bevacizumab compared to FOLFOX alone. Based on these results, bevacizumab was eventually approved for first- and second-line treatments in patients with bevacizumab-naïve mCRC.

Given the improved toxicity profile and likely improved outcomes, regimens including infusional 5-FU were preferred over bolus 5-FU to be used in combination therapy.\(^{33}\) Fuchs et al conducted a randomized study evaluating three different IFL-containing regimens in first-line mCRC: 1) FOLFIRI with bevacizumab, 2) IFL in combination with bolus 5-FU/L V (mIFL) with bevacizumab, and 3) IFL plus capecitabine.\(^{34}\) Patients who received FOLFIRI with bevacizumab had a significantly greater OS compared to those who received mIFL with bevacizumab (median OS, 19.2 months; \( P=0.007 \); HR for death =2.34; 95% confidence interval [CI] 1.34–4.12).\(^{34}\) Additionally, the combination of FOLFIRI with bevacizumab had an improved toxicity profile.\(^{34}\) A similar design with oxaliplatin-based therapy was conducted by Hochster et al.\(^{35}\) The TREE-2 trial was a Phase II study that randomized treatment-naïve mCRC patients to bevacizumab with different fluoropyrimidines and oxaliplatin regimens. The study demonstrated a median OS of 26.1 months and RR of 52% with tolerable adverse effects.\(^{35}\) It is also suggested that a bolus 5-FU regimen is less desirable than an infusional regimen. A larger randomized Phase III study by Saltz et al suggested that the combination of bevacizumab with first-line chemotherapy (either capecitabine plus oxaliplatin or 5-FU/ folinic acid plus oxaliplatin), compared to placebo, improved PFS (9.4 vs 8.0 months; HR 0.83; 97.5% CI 0.72–0.95; \( P=0.0023 \)), however, with no significant differences in OS or RR.\(^{36}\) The lack of OS and RR benefit was postulated to be secondary to the inability of bevacizumab to be continued at the time of progression.

Most recently, the MAVERICC trial, a large Phase II randomized study, evaluated mFOLFOX6 with bevacizumab vs FOLFIRI with bevacizumab as first-line chemotherapy in patients with treatment-naïve mCRC. Outcome results from this study suggest that FOLFIRI may have an edge over FOLFOX when combined with bevacizumab, although both the regimens remain acceptable in this setting (Table 1).\(^{37}\)

Bevacizumab with triplet chemotherapy

A combination of 5-FU, oxaliplatin, and IFL, FOLFOXIRI, was initially evaluated with bevacizumab in a Phase 2 study and showed interesting outcomes with a RR of 77%, median PFS of 13.1 months, and median OS of 30.9 months.\(^{38}\) Based on these results, a randomized Phase III study was conducted evaluating FOLFOXIRI with bevacizumab in comparison to
FOLFIRI with bevacizumab (TRIBE). A total of 508 patients with untreated mCRC were enrolled in either treatment arm. The median PFS was 12.1 months in FOLFIRI with bevacizumab compared to 9.7 months in FOLFIRI with bevacizumab. In addition, there was a significantly higher toxicity profile when compared to FOLFIRI with bevacizumab, and OS was not significantly different between both the groups.39 Additionally, there were no meaningful differences in the liver resection or R0 resection rates between the two arms.

To investigate further the potential benefits of adding bevacizumab to a triplet drug combination vs a doublet, STEAM was designed as a Phase II randomized three-arm study evaluating the combination of bevacizumab with concurrent FOLFIRI and sequential sFOLFIRI (c+s FOLFIRI; FOLFOX and FOLFIRI alternating every two cycles) compared to FOLFOX. The preliminary results from this trial suggest improved trends for RR and PFS with c+s FOLFIRI vs FOLFOX. In the 280 patients in the study, RR was 47% with FOLFOX/bevacizumab, 60% with sFOLFIRI/bevacizumab (odds ratio [OR] 1.7, 90% CI 1.05, 2.77; P=0.075), and 62% with cFOLFIRI/bevacizumab (OR 1.8, 90% CI 1.12, 2.97; P=0.040). Furthermore, PFS was 11.7 months (HR 0.672, 90% CI 0.489, 0.922) with cFOLFIRI/bevacizumab, 10.7 months with sFOLFIRI/bevacizumab (HR 0.738, 90% CI 0.537, 1.012), and 9.3 months with FOLFOX/bevacizumab.39 Additionally, STEAM suggests that the triplet strategy added to bevacizumab may improve the liver resection or R0 resection rates. The combined results of TRIBE and STEAM suggest that a select group of patients would benefit from triplet chemotherapy plus bevacizumab.

Bevacizumab in patients who are unable to tolerate intensive chemotherapy

Many patients are not candidates for cytotoxic combination chemotherapy due to comorbidities, poor performance status, age, and/or end organ dysfunction. For this group of patients, treatment guidelines recommend first-line therapy with 5-FU or capcitabine with or without bevacizumab.41

Earlier, two Phase II randomized studies evaluating 5-FU in combination with bevacizumab compared to 5-FU alone in patients with untreated mCRC suggested overall improvement in outcome measures with the addition of bevacizumab.29,42 Additionally, a recent Phase III study evaluated 407 patients who were randomized to receive capcitabine, capcitabine + bevacizumab, or capcitabine + bevacizumab + mitomycin-c. The findings from this study demonstrated

### Table I Bevacizumab as first-line therapy

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase</th>
<th>Treatment arms</th>
<th>PFS (months)</th>
<th>OS (months)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hurwitz et al29,31</td>
<td>III</td>
<td>IFL/Bevacizumab</td>
<td>10.6</td>
<td>20.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IFL/Placebo</td>
<td>6.2</td>
<td>15.6</td>
<td>NR</td>
</tr>
<tr>
<td>Fuchs et al10,14</td>
<td>III</td>
<td>FOLFIRI</td>
<td>7.6</td>
<td>23.1</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>mFL</td>
<td>5.9</td>
<td>17.6</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CapeIRI</td>
<td>5.8</td>
<td>18.9</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FOLFIRI/Bevacizumab</td>
<td>NR</td>
<td>Not reached</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>mIFL/Bevacizumab</td>
<td>NR</td>
<td>19.2</td>
<td>NR</td>
</tr>
<tr>
<td>Saltz et al34</td>
<td>III</td>
<td>XELOX or FOLFOX/placebo</td>
<td>8.0</td>
<td>19.9</td>
<td>0.077</td>
</tr>
<tr>
<td></td>
<td></td>
<td>XELOX or FOLFOX/bevacizumab</td>
<td>9.4</td>
<td>21.3</td>
<td>NR</td>
</tr>
<tr>
<td>Hochster et al35</td>
<td>III</td>
<td>mFOLFOX6/Bevacizumab</td>
<td>NR</td>
<td>26.1</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FOLFOX/Bevacizumab</td>
<td>NR</td>
<td>20.4</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CapOx/Bevacizumab</td>
<td>NR</td>
<td>24.6</td>
<td>NR</td>
</tr>
<tr>
<td>Kabbinavar et al39</td>
<td>II</td>
<td>5-FU + LV/Bevacizumab</td>
<td>9.2</td>
<td>16.6</td>
<td>0.16</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5-FU + LV/Placebo</td>
<td>5.5</td>
<td>12.9</td>
<td>NR</td>
</tr>
<tr>
<td>Tebbutt et al33</td>
<td>III</td>
<td>Capecitabine</td>
<td>5.7</td>
<td>18.9</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CB</td>
<td>8.4</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CBM</td>
<td>8.4</td>
<td>16.4</td>
<td>NR</td>
</tr>
<tr>
<td>Masi et al38</td>
<td>II</td>
<td>FOLFIRI/Bevacizumab</td>
<td>13.1</td>
<td>30.9</td>
<td>NR</td>
</tr>
<tr>
<td>Loupakis et al39</td>
<td>II</td>
<td>FOLFIRI/Bevacizumab</td>
<td>9.7</td>
<td>25.8</td>
<td>0.003</td>
</tr>
<tr>
<td>Lenz et al37</td>
<td>II</td>
<td>mFOLFIRI/6/bev</td>
<td>10.1</td>
<td>23.9</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FOLFIRI/bev</td>
<td>12.6</td>
<td>27.5</td>
<td>NR</td>
</tr>
</tbody>
</table>

Notes: *PFS was statistically significant in this study; OS was not statistically significant. In this study, OS was reported with capcitabine, mitomycin, and bevacizumab. NS, both PFS and OS were not significant in this study.

Abbreviations: PFS, progression-free survival; OS, overall survival; IFL, irinotecan; 5-FU, 5-fluorouracil; LV, leucovorin; CB, capcitabine plus bevacizumab; CBM, capcitabine, bevacizumab, and mitomycin; bev, bevacizumab; NR, not reported; NS, not significant; CapeIRI, capcitabine plus irinotecan.
an improvement in PFS in all treatment regimens containing bevacizumab vs capecitabine alone.\textsuperscript{45}

AVEX is a randomized Phase III study on the combination of bevacizumab and capecitabine vs capcitabine, focusing on an elderly population of patients with mCRC.\textsuperscript{44} In this study, a total of 280 patients were randomized to receive bevacizumab plus capecitabine or capcitabine alone. Patients in the bevacizumab plus capcitabine group had improved PFS (9.1 vs 5.1 months, HR 0.53, 95% CI 0.41–0.69; \( P < 0.0001 \)), overall response (19% vs 10%, \( P = 0.04 \)), and disease control rate (74% vs 58%, \( P = 0.01 \)).\textsuperscript{44} Additionally, the combination was well tolerated in this patient population.

The role of bevacizumab as maintenance therapy in mCRC

Given the adverse effect profile of cytotoxic combination chemotherapy, maintenance strategies following induction therapy were designed to maximize benefit while improving the tolerability profile (Table 2).

The Phase III MACRO trial is a study where patients were randomized prior to induction therapy to either bevacizumab or XELOX/bevacizumab maintenance after six cycles of XELOX/bevacizumab induction therapy.\textsuperscript{45} In this study, the median OS slightly favored the continuous arm group (23.2 months in the continuous arm vs 20.0 months in the bevacizumab arm, HR 1.05, 95% CI 0.85–1.30, \( P = 0.10 \)), overall response (19% vs 10%, \( P = 0.04 \)), and disease control rate (74% vs 58%, \( P = 0.01 \)).\textsuperscript{44} Additionally, the combination was well tolerated in this patient population.

## Table 2 Bevacizumab as maintenance therapy

<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment arms</th>
<th>PFS (months)</th>
<th>OS (months)</th>
<th>( P )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diaz-Rubio et al\textsuperscript{45}</td>
<td>Bevacizumab vs XELOX + bevacizumab</td>
<td>10.4 vs 9.7</td>
<td>20 vs 23.2</td>
<td>NS</td>
</tr>
<tr>
<td>Koeberle et al\textsuperscript{46}</td>
<td>Bevacizumab vs drug holiday</td>
<td>4.1 vs 2.9</td>
<td>25.4 vs 23.8</td>
<td>NS</td>
</tr>
<tr>
<td>Yalcin et al\textsuperscript{47}</td>
<td>XELOX + bevacizumab vs capcitabine + bevacizumab</td>
<td>8.3 vs 11</td>
<td>20.2 vs 23.8</td>
<td>0.002\textsuperscript{4}</td>
</tr>
<tr>
<td>Simkens et al\textsuperscript{48}</td>
<td>Bevacizumab + capcitabine vs drug holiday</td>
<td>11.7 vs 8.5</td>
<td>21.6 vs 18.1</td>
<td>PFS: &lt;0.0001</td>
</tr>
<tr>
<td>Bennouna et al\textsuperscript{49}</td>
<td>*Drug holiday vs bevacizumab vs bevacizumab + capcitabine</td>
<td>6.9 vs 6.1</td>
<td>20.2 vs 21.9</td>
<td>NS</td>
</tr>
</tbody>
</table>

Notes: \*Only PFS was significant in this study. In this study, there were three groups; however, analysis was done on time to progression for only bevacizumab vs bevacizumab + capcitabine.

Abbreviations: PFS, progression-free survival; OS, overall survival; NS, not significant.
Similarly, another study also showed that patients with lower pretreatment levels of VEGF-A and hepatocyte growth factor experienced an improvement in PFS and OS in comparison to patients with high VEGF-A levels. This was further validated in prospective trial done by Bruhn et al where the authors demonstrated that high levels of VEGF-A were associated with a poor prognosis due to a shorter PFS (HR =1.55, \( P=0.008 \)) compared to low VEGF-A levels.

Furthermore, Uysal et al investigated whether any clinical features in patients who received bevacizumab were associated with patient outcomes. The authors found that median PFS was 7.2 months in patients with basal proteinuria above 114 mg/day compared to 12 months in those with equal or lower proteinuria (\( P=0.01 \)). Similarly, PFS was shorter in patients with high lactate dehydrogenase (LDH) tension were associated with improved clinical outcomes (\( P=0.022 \) and \( P=0.04 \), respectively). However, patients who experienced hypertension were associated with improved clinical outcomes (\( P=0.034 \)). A meta-analysis done by Chen et al reaffirmed that bevacizumab-related hypertension could be potential biomarker for efficacy in mCRC. Furthermore, Khoja et al also showed that patients who developed proteinuria during therapy have a poorer survival. The median OS was 22.9 months for patients with grade 0 to 1 and 4.2 months for those with grade \( \geq 2 \) (Table 3).

Currently, there are no established predictive molecular or genetic biomarkers to better select patients who may (or may not) benefit from anti-angiogenic therapy.

### Bevacizumab should not be combined with anti-EGFR therapies in the first-line setting

Treatment with single targeted agents is often limited secondary to acquired resistance through compensatory activation of alternative signaling pathways. One mechanism to overcome resistance included combining novel agents that target multiple signaling pathways, where preclinical evidence suggests that inhibiting both VEGF and EGFR can improve antitumoral activity. BOND-2, a randomized Phase II trial, investigated the combination of bevacizumab, IFL and cetuximab, or bevacizumab and cetuximab. Patients who received the three-drug combination experienced an absolute 3.1-month survival benefit.

CAIRO-2, which is a randomized Phase III trial, did not confirm the survival benefit of combining bevacizumab with cetuximab. In this study, patients who received dual antibody therapy experienced a worse median PFS in comparison to patients in the bevacizumab arm (9.8 vs 10.7 months; \( P=0.019 \)), suggesting that the combination is not more efficacious than with single agents, and may actually lead to worse outcomes. This was consistent with the results of another Phase III study, the PACCE trial, that assessed the role of another EGFR antibody, panitumumab, with bevacizumab and chemotherapy. The panitumumab cohort experienced worse outcomes and a higher level of toxicities. These two studies suggest that the combination of bevacizumab and an anti-EGFR agent with chemotherapy should not be used in patients treated in first line with mCRC. Ongoing studies continue to evaluate the role of this strategy in more refractory settings.

### VEGF vs EGFR inhibitors in the first-line treatment of non-mutated RAS mCRC: which biologic first?

Numerous studies suggested that agents targeting VEGF or EGFR when added to cytotoxic combination chemotherapy improve outcome in patients with mCRC. The question of which biologic is preferable in the first-line treatment of non-mutated \( \text{RAS} \) mCRC has been recently addressed. Heinemann and Stintzing conducted a randomized Phase III trial (FIRE-3) in which patients received FOLFIRI + cetuximab or FOLFIRI + bevacizumab. There was no significant difference in the primary end point of overall RR (cetuximab: 65.3% response [95% CI 58.3–61.1] vs bevacizumab 58% [95% CI 52.1–63.7], OR 1.18, 95% CI 0.85–1.64, \( P=0.18 \)). The median PFS was similar in both the groups (10 months [95% CI 8.8–10.8] in the cetuximab group and 10.3 months in the bevacizumab group [HR 1.06, 95% CI 0.88–1.26; \( P=0.55 \)].

Surprisingly, when evaluating \( \text{RAS} \text{WT} \) patients, OS was better in patients who were treated with cetuximab (OS 33.1 vs 25.6 months favoring cetuximab over bevacizumab, \( P=0.011 \)).

CALGB 80405 is a large randomized Phase III trial in which patients with \( \text{KRA} \text{S} \text{WT} \) tumors received either FOLFIRI or FOLFOX at enrollment and were then randomized to either bevacizumab or cetuximab. The original trial included unselected patients for \( \text{RAS} \) status.
who were randomized to either bevacizumab, cetuximab, or both. The findings demonstrated similar results across all the four groups, suggesting that either chemotherapy backbone in combination with either an anti-EGFR or anti-VEGF therapy is an acceptable therapy option in those with RAS WT tumors (OS: chemotherapy/bevacizumab vs chemotherapy/ cetuximab = 31.2 vs 32 months [P = 0.40]; PFS: chemotherapy/ bevacizumab versus chemotherapy/cetuximab = 11.3 vs 11.4 months [P = 0.31]) (Table 4). In this study, RAS WT patients treated with FOLFIRI with bevacizumab experienced a median OS of 35.2 months in comparison to 32 months in the cetuximab arm (P = 0.7).

The collective results from FIRE 3 and CALGB 80405 suggest that addition of bevacizumab or cetuximab confers a similar advantage when combined with chemotherapy in the first-line treatment of patients with mCRC.

The role of bevacizumab beyond progression

TML 18147 was a multicenter, prospective, randomized, open-label, Phase III trial that evaluated the continuation of bevacizumab following progression on first-line chemotherapy (either oxaliplatin or IFL) with bevacizumab in patients with mCRC. In this study, patients were randomized to receive either bevacizumab with chemotherapy (N = 409) or chemotherapy alone (N = 411). There was an improvement in median OS for patients in the bevacizumab plus chemotherapy group (11.1 vs 9.8 months, P = 0.0062).60

In addition to bevacizumab, two other anti-angiogenic agents have been approved in mCRC following progression on bevacizumab. The first of these agents is aflibercept (ziv-aflibercept), a fully human recombinant fusion protein that is designed to target VEGF-A, VEGF-B, and placental growth factor. The VELOUR trial is a randomized Phase III study that assessed the role of aflibercept in patients who progressed on prior oxaliplatin therapy and were randomized to receive FOLFIRI with or without aflibercept. Patients who received aflibercept had a significantly longer median OS (13.5 vs 12.06 months, HR 0.817, P = 0.0032). A subgroup analysis of the 30% of patients who progressed on bevacizumab confirmed a similar clinical benefit, although the magnitude of survival improvement was less significant. Unfortunately, the administration of ziv-aflibercept to FOLFIRI enhanced cytotoxic-related toxicities in addition to the expected target specific ones.

The other agent, ramucirumab, is a human monoclonal antibody that targets vascular endothelial growth factor receptor-2. The RAISE trial, a multicenter randomized Phase III study, evaluated the efficacy of ramucirumab in patients with mCRC as a second-line treatment. Unlike VELOUR, in this study, all patients progressed on bevacizumab in first line. In this trial, a total of 1,072 patients who failed prior treatment with FOLFOX and bevacizumab were randomized to FOLFIRI with or without ramucirumab. There was a significant improvement in both OS and PFS (13.3 vs 11.7 months and 5.7 vs 4.5 months, respectively).62

The results of these studies suggest a benefit from continuation of VEGF inhibition following prior exposure to bevacizumab. The effects across all studies are of similar magnitude (Table 5). Given cost and toxicity considerations, bevacizumab beyond progression remains the preferable

| Table 4 Anti-VEGF versus anti-EGFR therapy in first-line treatment of non-mutated RAS mCRC |
|--------|---------|-------|-------|-------|
|        | PFS (months) | P-value | OS (months) | P-value |
| KRAS WT |             |        |       |       |
| FIRE-317 | Cetuximab + FOLFIRI | 10.0 | 0.55 | 28.7 | 0.017 |
|          | Bevacizumab + FOLFIRI | 10.3 |       | 25.0 |       |
| CALGB 8040563 | Cetuximab + FOLFOX/FOLFIRI | 10.4 | 0.55 | 29.9 | 0.34 |
|          | Bevacizumab + FOLFOX/FOLFIRI | 10.8 |       | 29.0 |       |
| RAS WT |             |        |       |       |
| FIRE-317 | Cetuximab + FOLFIRI | 10.4 | 0.54 | 33.1 | 0.0059 |
|          | Bevacizumab + FOLFIRI | 10.2 |       | 25.0 |       |
| CALGB 8040563 | Cetuximab + FOLFOX/FOLFIRI | 11.4 | 0.31 | 32.0 | 0.40 |
|          | Bevacizumab + FOLFOX/FOLFIRI | 11.3 |       | 31.2 |       |

Abbreviations: VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor; mCRC, metastatic colorectal cancer; PFS, progression-free survival; OS, overall survival; WT, wild-type.

| Table 5 Anti-VEGF after progression with bevacizumab |
|--------|--------|--------|-------|
| Study   | Treatment arms | Phase | PFS (months) | OS (months) | P-value |
| Bennouna et al60 | Second-line chemotherapy (oxaliplatin or irinotecan) + bevacizumab | III | NR | 11.1 | 0.0062 |
| Van Cutsem et al61* | FOLFIRI + aflibercept vs FOLFIRI + placebo | III | NR | 13.5 | 0.0032 |
| Tabernero et al62 | FOLFIRI + ramucirumab vs FOLFIRI + placebo | III | 5.7 | 13.3 | 0.0219 |

Note: Approximately 30% of patients in this study were exposed to bevacizumab in the first line.

Abbreviations: PFS, progression-free survival; OS, overall survival; NR, not reported.
anti-angiogenic agent. EGFR inhibitors are acceptable alternatives in the RAS WT group of patients.

Conclusion
In conclusion, outcome of patients with mCRC has improved significantly over the last two decades and is approaching the 3-year mark. The enhanced outcome has been primarily driven by the expanding armamentarium of agents available to clinics including anti-VEGF therapies such as bevacizumab. Despite improvements in therapy, there remains a noticeable absence of a predictive biomarker to help select patients who are likely to benefit from anti-VEGF therapy.

Disclosure
The authors report no conflicts of interest in this work.

References


37. Lenz H-J, Lee F, Yau L, et al. MAVERICC, a phase 2 study of mFOLFOX6–bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). *J Clin Oncol.* 2016;34(suppl 4S, abstr 493).


40. Johanna C, Bendell JRT, James AR, et al; Sarah Cannon Research Institute; Washington University School of Medicine; Florida Cancer Specialists; The Center for Cancer and Blood Disorders; The West Clinic, Memphis; USC Norris Comprehensive Cancer Center; Yale University; Genentech Inc; Duke University Medical Center. Overall response rate (ORR) in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) vs FOLFOX-BEV for the first-line (1L) treatment (ts) of patients (pts) with metastatic colorectal cancer (mCRC). *J Clin Oncol.* 2016;34(suppl 4S, abstr 492).


63. Venoook AP, Niedzwiecki D, Heinz-Josef Lenz, et al. Cancer and Leukemia Group B (Alliance), SWOG, and ECOG. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFoX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). *J Clin Oncol.* 2013;31:5s, 2014 (suppl; abstr LBA3).